Altamira Therapeutics Ltd. (CYTO): Net earnings per share growth forecast for next year
Liquidity shortages and legal disputes are putting pressure on the market capitalization of Altamira Therapeutics (CYTO). However, strategic M&A deals to implement Peptide+ and streamlined chemical component logistics sustain growth potential. The trend of market expectations for EPS growth on the GURU.Markets chart reflects the consensus reaction to these factors, where the 56.10 mark indicates the current level of analyst profit forecasts.
Financial and market metric breakdowns for Altamira Therapeutics Ltd. (CYTO)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- company book value details:
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Altamira Therapeutics|CYTO - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Altamira Therapeutics Ltd|CYTO - Company Aggregate Debts|Debt to Book Capitalization Ratio Altamira Therapeutics|CYTO - Company Long-Term Liabilities|Company Short-Term Debts Altamira Therapeutics|Quick Liquidity altamiratherapeutics.com
- earnings and valuation multiples information:
CYTO - Final Profit|Projected Future Earnings Altamira Therapeutics|CYTO - P/E Multiple|Projected Price to Earnings Altamira Therapeutics Ltd|CYTO - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Altamira Therapeutics|CYTO - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Altamira Therapeutics|CYTO - Earnings per share for the trailing year|Quarterly EPS earnings growth altamiratherapeutics.com|CYTO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Altamira Therapeutics
- revenue and sales proceeds data:
Basic company analysis:CYTO, Altamira Therapeutics
This indicator measures the dynamics of analysts' consensus earnings forecasts for the coming year, allowing investors to filter out market noise and identify a genuine fundamental business turnaround. The forward net income trend reflects the effectiveness of Altamira Therapeutics (CYTO) transformation toward RNA delivery nanotechnologies and the licensing of new developments, which is critical for assessing capital growth potential.
Analysis of competing companies
HLN (Haleon Group) - Earnings growth forecast for next year|Expected net earnings per share growth next year Kenvue Health KVUE|Net earnings per share growth forecast for next year Verona Pharma plc (VRNA)|MENS (jyongbio.com) - Expected earnings per share trend next year|Earnings growth forecast for next year LGND (Ligand)|Earnings growth forecast for next year Amneal Pharmaceuticals, Inc. AMRX|PRGO - Net earnings per share growth forecast for next year|ALVO: Net earnings per share growth forecast for next year|LQDA (Liquidia Corporation) - Expected earnings per share growth for next year|GLPG: Projected earnings per share increase next year|ANIP (ANI Pharmaceuticals, Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year MannKind Corp|Net earnings per share growth forecast for next year Amphastar (AMPH)|Expected earnings per share growth for next year Pacira Corp PCRX|Earnings growth forecast for next year SPRY (ARS Pharmaceuticals)|Consensus forecast of earnings per share growth for next year theravance.com (TBPH)|AQST - Net earnings per share growth forecast for next year|Expected earnings per share trend next year SCPH (scPharmaceuticals Inc.)|TECX: Earnings growth forecast for next year|Tonix Pharmaceuticals Holding (TNXP) - Earnings growth forecast for next year|Expected earnings per share growth for next year SXTC|EPRX: Expected earnings per share trend next year|Expected earnings per share growth for next year BHST (BioHarvest Sciences Inc.)|Projected earnings per share increase next year EXOZ|Earnings growth forecast for next year ORMP (Oramed Pharmaceuticals Inc.)|Expected earnings per share trend next year ENTX|MindWalk Holdings - Earnings growth forecast for next year|Expected net earnings per share growth next year abvcpharma.com|Cumberland Pharmaceuticals Inc. (CPIX) - Net earnings per share growth forecast for next year|Quantum BioPharma Ltd. - Expected earnings per share trend next year|FGEN (FibroGen Corp) - Earnings growth forecast for next year|Earnings growth forecast for next year Telomir Pharmaceuticals Corp|Net earnings per share growth forecast for next year Rani Therapeutics (RANI)|SNYR: Net earnings per share change forecast for next year|Earnings growth forecast for next year RLYB (Rallybio)|Lexaria Bioscience Corp (LEXX) - Expected net earnings per share growth next year|PULM: Expected earnings per share growth for next year|PTHL - Earnings growth forecast for next year|APM (aptorumgroup.com) - Expected earnings per share growth for next year|LYRA: Projected earnings per share increase next year|IBO (Impact BioMedical Inc) - Earnings growth forecast for next year|TNF Pharma (TNFA) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year YCBD|Expected earnings per share growth for next year PainReform Corp PRFX|Net earnings per share growth forecast for next year Lipella Pharmaceuticals LIPO|Consensus forecast of earnings per share growth for next year optinose.com (OPTN)|Pieris Pharmaceuticals, Inc. - Earnings growth forecast for next year|Procaps Group (PROC) - Expected earnings per share growth for next year|PTPI (Petros) - Expected earnings per share growth for next year|Expected net earnings per share growth next year Qilian International Corp (QLI)|Expected earnings per share growth for next year SLRN|TFFP (tffpharma.com) - Projected earnings per share increase next year
